Skip to main content
  1. Home
  2. Emerging Tech
  3. News

Makerarm is a digital fabrication system that lets virtually anyone make virtually anything

Add as a preferred source on Google

Imagine if you could roll every technological tool for creatives into one workspace-sized robotic arm. Sounds pretty excellent, right? Well Makerarm –a freshly-launched Kickstarter gizmo– does just that by combining the functionality of a 3D printer, laser cutter, etcher and embosser, ink printer, design assistant, bakery decorator, and more into a single robotic creativity machine.

So how can one machine boast so many functions? The key is Makerarm’s system of interchangeable heads, which adapt its output to suit the user’s needs. In the demo video below, Makerarm is shown executing visual art pieces, creating plastic parts, etching wood and leather, drawing on paper, and even icing a cake.

 

But Makerarm aims to be more than just the sum of its parts. Despite the fact that it’s a multipurpose machine, Makerarm outdoes standalone creativity tools in certain applications. As a 3D printer, for example, Makerarm prints free from the confines of a typical box printer, and even includes interchangeable attachments for fused filament fabrication (FFF) printing, and stereolithography (SLA) printing.

Recommended Videos

Makerarm will also come with a hardware development kit so that creators can dream up and execute their own interchangeable tool heads to suit specific project needs. Of course, Makerarm will also be completely programmable and Wi-Fi enabled, so makers can train a pair or even a fleet of Makerarms to work in tandem, and can program new functions remotely.

The Kickstarter campaign for Makerarm will run until November 10th, but they’re already well on their way to the funding goal of $349,750. If all goes as planned, Makerarm’s creators expect to begin shipping sometime around October 2016, assuming the campaign is successfully funded.

Chloe Olewitz
Former Digital Trends Contributor
Chloe is a writer from New York with a passion for technology, travel, and playing devil's advocate. You can find out more…
Students who use AI every day may be falling behind, while moderate users pull ahead
New global testing data suggests more AI in the classroom isn't automatically better.
Logo, Text

I assumed more AI access might help students learn faster. However, a new OECD study dispels that misconception for me and everyone else who gave their children a paid version of AI chatbots, thinking it would help them through their educational journey. 

According to PISA 2025 data from 760,000 students in 91 countries, students who use AI daily score meaningfully worse on standardized tests than their peers. The full picture is more complicated than a simple ban would fix.

Read more
XPENG just put its humanoid robot on the production line, and it walked itself out
IRON clocks in for its first shift
XPENG Iron

XPENG’s humanoid robot has officially joined the workforce, and it even got an employee badge. The Chinese automaker announced on September 8 that its next-generation IRON had completed assembly and autonomously walked off its newly commissioned humanoid robot production line in Guangzhou.

CEO He Xiaopeng then pinned a staff badge onto the robot, symbolically welcoming it to the XPENG team. It is a charming little ceremony for a machine that the company hopes will eventually become a regular part of everyday life. XPENG is moving IRON beyond R&D prototypes toward production-line manufacturing, applying the quality-control systems and manufacturing experience it has developed through its electric vehicle business.

Read more
An AI-designed drug might help slow aging, but we’re not there yet
The results hint at a possible anti-aging effect, but there’s still a long way to go before we know what it means.
medical test tubes

Rentosertib, a drug Insilico Medicine designed almost entirely using AI, was created to treat idiopathic pulmonary fibrosis, a disease that scars and stiffens the lungs over time. But fighting lung disease was only half the plan from the start.

According to a new study published in Nature Biotechnology, the drug's target was chosen specifically because it overlaps heavily with the biology of aging, and the whole trial was designed to test whether treating the lungs could also mean turning back the body's biological clock.

Read more